FDA Approves Label Expansion for Merck’s Welireg in Kidney Cancer

Key Facts

1The FDA expanded the label for Merck's Welireg to include a new indication for the treatment of advanced kidney cancer.

The FDA expanded the label for Merck's Welireg to include a new indication for the treatment of advanced kidney cancer. Zacks reported that this approval marks the third indication for the drug in the kidney cancer segment as adoption and sales continue to grow.

MRK closed at $148.74 on September 25, 2026, having reached a day high of $149.94 and a low of $147.48 during that session. The regulatory milestone follows clinical data supporting the drug's efficacy in a broader patient population within the oncology market.